New hope for Drug-Resistant TB: shorter, safer treatment on the horizon?
NCT ID NCT06441006
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 38 times
Summary
This study tests whether a shorter treatment regimen (13-24 weeks) using a combination of drugs (bedaquiline, linezolid, pretomanid, and moxifloxacin) works as well as the standard longer treatment for people with a type of drug-resistant tuberculosis. About 400 adults with fluoroquinolone-susceptible multidrug-resistant TB will be randomly assigned to different treatment lengths. The goal is to find a regimen that cures patients with fewer side effects and less time on medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hanoi Lung Hospital
NOT_YET_RECRUITINGHanoi, Vietnam
Contact
Contact
-
Hospital Nacional Sergio E. Bernales
NOT_YET_RECRUITINGLima, Peru
Contact
Contact
-
Institute of Chest Diseases
NOT_YET_RECRUITINGKotri, Pakistan
Contact
-
Mulago National Referral Hospital
NOT_YET_RECRUITINGKampala, Uganda
Contact
-
National Center for Communicable Diseases
RECRUITINGUlaanbaatar, Mongolia
Contact
-
Policlínico SES
NOT_YET_RECRUITINGLima, Peru
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bedaquiline, linezolid, pretomanid, moxifloxacin
What this could lead to
If successful, this trial could lead to shorter, more effective treatment regimens for multidrug-resistant tuberculosis, reducing side effects and improving cure rates.
What could go wrong
This is an early-to-mid-stage trial with only 400 participants, so results may not apply to all patients. There are risks of serious side effects from the drugs, and the shorter treatment may not work as well as standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.